Acrivon Therapeutics, Inc. Common StockACRVNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-17.51%
↓ 201% below average
Average (16q)
17.28%
Historical baseline
Range
High:97.28%
Low:-32.31%
Volatility
750.0%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -17.51% |
| Q2 2025 | 4.98% |
| Q1 2025 | -15.89% |
| Q4 2024 | -2.85% |
| Q3 2024 | 25.55% |
| Q2 2024 | 33.57% |
| Q1 2024 | -26.62% |
| Q4 2023 | 49.30% |
| Q3 2023 | -2.41% |
| Q2 2023 | 7.82% |
| Q1 2023 | 66.46% |
| Q4 2022 | -26.19% |
| Q3 2022 | 94.80% |
| Q2 2022 | -32.31% |
| Q1 2022 | 97.28% |
| Q4 2021 | 37.77% |
| Q3 2021 | 0.00% |